William G Wierda, MD, University of Texas MD Anderson Cancer Center

home / authors / william-g-wierda-md-university-of-texas-md-anderson-cancer-center

Articles

Rapid Readouts: Phase 1 Cohort of TRANSCEND-CLL-004 Study

Rapid Readouts: Phase 1 Cohort of TRANSCEND-CLL-004 Study

William G Wierda, MD, University of Texas MD Anderson Cancer Center
October 21st 2021

William G. Wierda, MD, discusses data from the phase 1 cohort of lisocabtagene maraleucel combined with ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia that was presented at the 19th International Workshop on CLL (iwCLL) held in September 2021.

Read More

CLL: Prognostic Markers

CLL: Prognostic Markers

William G Wierda, MD, University of Texas MD Anderson Cancer Center;John Allan, MD, Weill Cornell Medicine;Ehab Atallah, MD, Medical College of Wisconsin;Steven Coutre, MD, Stanford University Medical Center;Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center;Jennifer Woyach, MD, Ohio State University
July 20th 2021

An overview of prognostic models in chronic lymphocytic leukemia (CLL).

Read More

Prognostic Factors in Chronic Lymphocytic Leukemia

Prognostic Factors in Chronic Lymphocytic Leukemia

William G Wierda, MD, University of Texas MD Anderson Cancer Center;John Allan, MD, Weill Cornell Medicine;Ehab Atallah, MD, Medical College of Wisconsin;Steven Coutre, MD, Stanford University Medical Center;Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center;Jennifer Woyach, MD, Ohio State University
July 20th 2021

A discussion about prognostic factors in patients with newly diagnosed chronic lymphocytic leukemia (CLL).

Read More

Molecular Testing for Newly Diagnosed CLL

Molecular Testing for Newly Diagnosed CLL

William G Wierda, MD, University of Texas MD Anderson Cancer Center;John Allan, MD, Weill Cornell Medicine;Ehab Atallah, MD, Medical College of Wisconsin;Steven Coutre, MD, Stanford University Medical Center;Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center;Jennifer Woyach, MD, Ohio State University
July 13th 2021

Ehab Attallah, MD, provides an overview of molecular testing for patients with newly diagnosed chronic lymphocytic leukemia (CLL).

Read More

Latest Updated Articles

Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data